# Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

> **NCT00003992** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 200 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** paclitaxel
- **DRUG:** tamoxifen citrate

## Key facts

- **NCT ID:** NCT00003992
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** 2007-01
- **Final completion:** 2009-03
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003992, "Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*